Elutia Inc. (NASDAQ: ELUT) announced on October 1, 2025 that it has closed the sale of its BioEnvelope business, which includes the EluPro™ antibiotic‑eluting bioenvelope and the CanGaroo® bioenvelope, to Boston Scientific Corporation (NYSE: BSX) for $88 million in cash.
The transaction provides Elutia with a substantial cash infusion that strengthens its balance sheet and enables the company to focus resources on the development and launch of its NXT‑41x biomatrix platform for breast reconstruction, a $1.5 billion U.S. market opportunity.
By divesting the BioEnvelope line, Elutia eliminates the product liability and regulatory risks associated with those assets and can concentrate on its core drug‑eluting biomatrix technology, positioning the company for higher‑margin growth in the breast‑reconstruction segment.
For investors, the $88 million cash proceeds improve liquidity, reduce reliance on external financing, and support the company’s strategic shift toward a more focused, high‑potential product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.